Recce Pharma (ASX:RCE) has announced it’s further boosting its role as an emerging defence company operating in the US military supply chain.
In April this year, the company notified the market it had started applying for a US defence research grant.
Now, the company will have a presentation at the 2024 Military Health System Research Symposium (MHSRS).
Recce’s chief brains – executive chair Dr. John Prendergast, and, Chief Medical Advisor Alan Dunton M.D – will be at the presentation in-person to deliver a speech.
That session relates to “non-traditional” products to be used in the treatment of wound infections and sepsis – while the product is designed for a diverse range of infected tissues, the company has specifically engaged the US DoD on the grounds of burns research.
The company’s speech will hover around a study that saw Recce’s R327 applied against infections of Streptococcus pyogenes, known to infect burn sites, and the similar Clostridium perfringens bacteria.
The MHSRS is expected to attract around 4,000 attendees within the military sector (or closely related to it.) Recce described the conference as the DoD’s “foremost” such event. The event will be held in Florida on the 26th of August.
RCE last traded at 85.5cps.